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OBJECTIVES We sought to compare the protective efficacy of enalapril and losartan on lung diffusion in
chronic heart failure (CHF).
BACKGROUND In CHF, hydrostatic overload causes disruption of the alveolar-capillary membrane and
depression of carbon monoxide diffusion (DCO); enalapril improves DCO through mecha-
nisms still undefined; and saline infusion in the pulmonary circulation worsens DCO,
putatively because of an upregulated sodium transport to the alveolar interstitium. We
investigated whether enalapril modulates sodium handling and whether losartan shares the
same properties.
METHODS In 29 patients with CHF, DCO, its membrane diffusion subcomponent (DM) and right atrial
and pulmonary wedge pressures were monitored during saline infusion, in the control
condition, during enalapril therapy (20 mg/day) for two weeks and after crossover to losartan
(50 mg/day) for two weeks (first 20 patients), or after the combination of enalapril with
aspirin (325 mg/day) for one week (last 9 patients).
RESULTS Saline, 150 ml, lowered DCO (27.9%; p , 0.01) and DM (29.9%; p , 0.01) without
hydrostatic variations. Responses to 750 ml of saline were qualitatively similar. After
treatment with enalapril, baseline DCO (p , 0.01) and DM (p , 0.01) were augmented; after
sodium loading, the percent reductions of DCO (p , 0.01) and DM (p , 0.01) were
comparable to those before it, resulting in higher absolute values. This suggests that the
greater the gas conductance improvement with enalapril, the lower the impedance with saline.
Losartan was ineffective on gas transfer at rest and under salt challenge. Aspirin counteracted
the benefits of enalapril.
CONCLUSIONS In CHF, enalapril protects lung diffusion, possibly through a prostaglandin-mediated
modulation of sodium overfiltration to the alveolar interstitium; losartan does not share this
ability. (J Am Coll Cardiol 2001;37:398–406) © 2001 by the American College of
Cardiology
As chronic heart failure (CHF) progresses, structural alter-
ations of the pulmonary microvascular endothelium and
alveolar interstitium develop and are associated with distur-
bances in gas exchange between blood and alveoli (1–3).
Angiotensin-converting enzyme (ACE) inhibition im-
proves, both in the short (3) and long term (4), the
pulmonary diffusing capacity for carbon monoxide (DCO) in
patients with CHF, but not in normal control subjects, by
facilitating the molecular diffusion across the alveolar-
capillary membrane (DM component of DCO) (5). Imped-
ance to gas transfer closely correlates with exercise intoler-
ance (2,6) and is refractory to conventional treatment of
heart failure and to heart transplantation (7,8). Therefore,
two important questions arise: what is the intimate enalapril
process? Do type 1 angiotensin receptor (AT1) blockers
share the same properties and mechanisms? As far as ACE
inhibitors are concerned, the prostanoid-mediated action of
bradykinin (3,9,10) seems to be involved; however, it is
unclear whether they affect the structural alterations of the
alveolar-capillary membrane, as such, or modulate the
functional consequences of these alterations. A disordered
salt filtration in the alveolar interstitial space might be an
example of functional deterioration. In fact, Puri et al. (11)
have reported that 10 ml/kg body weight of 0.9% saline
infused in patients in New York Heart Association
(NYHA) functional class I caused a depression of DM.
Consistently, an amount of saline as small as 150 ml infused
in the pulmonary artery of patients in functional class II/III
produced a similar effect, without eliciting any hydrostatic
variations; also, there was no measurable effect of saline on
the lung function of normal control subjects (12). These
data have been interpreted as reflecting an upregulation of
sodium transport to the alveolar interstitium in patients
with CHF, due to remodeling of the capillary wall in
response to increased wall stress (13).
We studied DCO, DM and pulmonary capillary blood
volume (Vc9) in patients with CHF while they were
receiving enalapril and after crossover to losartan. We also
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investigated the responses of these variables to the infusion
of saline in the pulmonary circulation, as well as their
variations produced by each of the two drugs.
METHODS
Patients. Male patients were referred to the Institute of
Cardiology, University of Milan, for evaluation of CHF.
Criteria for inclusion were: 1) chronic stable NYHA func-
tional class II/III due to cardiac dysfunction; and 2) left
ventricular ejection fraction (LVEF) #40%. Criteria for
exclusion were: 1) respiratory or renal disease and airway
obstruction; 2) DCO #70% of the normal value predicted on
the basis of standard nomograms incorporating age, gender,
weight and height (14); 3) current or past smoking status
(.10 cigarettes/day during one of the past five years); 4)
mitral regurgitation exceeding grade 3 on a subjective scale
from 0 to 5; and 5) use of ACE inhibitors, AT1 blockers,
acetylsalicylic acid or other cyclo-oxygenase inhibitors
within the last two months (3,4,9).
Twenty-nine patients completed the trial. In the first 20
patients (group 1), we investigated the responses to saline in
the control condition, while they were taking enalapril and
then while taking losartan. In the last nine patients (group
2), we investigated the responses to saline and their varia-
tions with enalapril alone and in combination with aspirin.
Group 1 comprised 13 patients in NYHA functional class II
and seven in class III; 17 of them had idiopathic dilated
cardiomyopathy and three had ischemic heart disease. In
group 2, five patients were in class II and four were in class
III; seven had dilated cardiomyopathy and two had ischemic
heart disease. None of these patients had participated in
previous studies in our laboratory.
The protocol was approved by the Institution Ethics
Committee, and written, informed consent was obtained
from each patient. The procedures followed were in accor-
dance with institutional guidelines.
Pulmonary functional evaluation. Vital capacity, total
lung capacity and forced expiratory volume in 1 s were
assessed with Sensor Medics 2200 Pulmonary Functional
Test System (Sensor Medics, Yorba Linda, California). The
diffusing capacity for carbon monoxide was determined
twice each time, with washout intervals of at least 4 min (the
average was taken as the final result), with a standard
single-breath technique (15). The measured diffusing capac-
ity was corrected for the patient’s hemoglobin concentra-
tion. The single-breath alveolar volume (VA) was derived by
methane dilution. Then, DCO/VA was calculated to account
for the reduction in pulmonary volume in CHF (16) and for
hypothetical volume variations with fluid infusion. The
diffusing capacities of the alveolar-capillary membrane (DM)
and the pulmonary capillary volume of blood available for
gas exchange (Vc9) were determined using the classic
method described by Roughton and Forster (17). We
obtained all measurements with a test gas containing 0.28%
carbon monoxide, 14% helium and 21% oxygen, with the
balance nitrogen. The DCO measurements were then re-
peated with a test gas containing 0.3% carbon monoxide,
10% helium and 89.7% oxygen. Studies of reproducibility
showed a high level of agreement between consecutive
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AT1 5 angiotensin type 1 receptor
CHF 5 chronic heart failure
DCO 5 diffusing capacity for carbon monoxide
DM 5 alveolar-capillary membrane diffusing capacity
HCT 5 hematocrit
LVEF 5 left ventricular ejection fraction
NE 5 norepinephrine
PRA 5 plasma renin activity
VA 5 alveolar volume
Vc9 5 pulmonary capillary blood volume
Figure 1. Study design.
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measurements of 1/DM, with a correlation coefficient of
0.96 and a coefficient of variation ,6%.
Study design. All patients were kept on stable optimal
doses of digoxin and furosemide, and none had signs of fluid
retention. After the screening tests, patients in groups 1 and
2 were placed on a constant isocaloric diet containing 130
mmol Na1, 90 mmol K1 and 1500 ml water per day for the
entire duration of the study. After five days of the controlled
diet, patients in group 1 were admitted to the Heart Failure
Unit, where confirmation of sodium balance was achieved
with urinary Na1, K1 and creatinine monitoring in the first
24 h. The protocol included infusion of 0.9% sodium
chloride solution in amounts of 150 ml (second 24 h) and
750 ml (third 24 h). Then, patients started receiving
enalapril (20 mg/day) in addition to the baseline treatment,
which was kept constant throughout the study period; they
were discharged from the hospital and readmitted two
weeks later for a repeat of the same procedures while
continuing enalapril. Subsequently, losartan (50 mg/day)
was substituted for enalapril, and the measurements were
repeated after two weeks while continuing losartan. The
first and second steps of the protocol in group 2 were similar
to those in group 1. In patients in group 2, the third study
step consisted of the combination of enalapril with aspirin
(325 mg/day). After a week, saline infusions and gas transfer
measurements were repeated with the same methods. The
duration of the study in groups 1 and 2, the infusion
sequences and the drug treatments are depicted in Figure 1.
The investigators had no knowledge of the patients’ clinical
condition and treatment. Studies were begun at 8 AM after
an overnight fast. A 5F triple-lumen, flow-directed,
balloon-tipped thermodilution catheter was introduced per-
cutaneously, under local anesthesia, into an antecubital vein
and advanced to the pulmonary circulation under fluoro-
scopic guidance in a recumbent position. Then, the patient’s
chest wall was elevated at 45° in a comfortable position,
which was maintained throughout the studies. For measure-
ment of water and Na1 excretion, urine was collected in the
3 h before and in the 3 h after saline infusion. Right atrial
and wedge pulmonary pressures were monitored through
each study. Saline infusions were made in the main stem of
the pulmonary artery at a rate of 0.2 ml/kg per min. The
DCO, DM and Vc9 values were determined twice in the 2 h
before infusion, soon after infusion and 1 and 2 h later. Ten
minutes before and after each infusion, mixed venous blood
was withdrawn for measurements of hematocrit (HCT),
hemoglobin, protein, aldosterone and norepinephrine (NE)
plasma concentrations, as well as plasma renin activity
(PRA). Cardiac output (thermodilution, average of two
determinations) and LVEF were also measured. Pulmonary
arteriolar resistance was calculated as mean pulmonary
artery pressure 2 mean wedge pulmonary pressure 3
1,332 3 60/cardiac output.
Laboratory methods. The severity of mitral regurgitation
was assessed by color Doppler velocimetry and was graded
Table 1. Demographic, Clinical and Laboratory Baseline Variables in the Study Groups
Group 1
(n 5 20)
Group 2
(n 5 9)
Age (yrs) 58 6 11 57 6 10
Gender M/F (n) 20/0 9/0
BSA (m2) 1.90 6 0.2 1.85 6 0.3
SBP/DBP (mm Hg) 128 6 8/80 6 4 123 6 7/80 6 3
Serum creatinine (mg/dl) 1.10 6 0.07 1.20 6 0.07
FEV1 (liters) 3.1 6 0.6 2.9 6 0.7
%Predicted 86 6 10 85 6 10
VC (liters) 3.5 6 0.7 3.6 6 0.7
%Predicted 78 6 12 80 6 12
TLC (liters) 4.9 6 0.6 5.1 6 0.8
%Predicted 79 6 10 82 6 9
Digoxin (mg/day) 0.25 6 0.07 0.25 6 0.04
Furosemide (mg/day) 70 6 30 83 6 30
DCO (ml/min per mm Hg) 22.5 6 5.0 22.0 6 7.0
%Predicted 79 6 4 78 6 5
DM (ml/min per mm Hg) 31 6 5 30 6 8
VC9 (ml) 129 6 20 128 6 25
LVEF (%) 30 6 5 32 6 4
CI (ml/min per m2) 2,347 6 400 2,395 6 400
Mean rap (mm Hg) 2.0 6 1.4 1.0 6 1.0
Mean WPP (mm Hg) 10.5 6 3.8 10 6 4
Urinary output (ml/24 h) 1,600 6 200 1,550 6 290
Urinary Na1 excretion (mmol/24 h) 96 6 5 101 6 4
MR (subjective scale) 1.5 6 0.1 1.7 6 0.2
Data are presented as the mean value 6 SD, except for gender.
BSA 5 body surface area; CI 5 cardiac index; DBP 5 diastolic blood pressure; DCO 5 pulmonary diffusing capacity for
carbon monoxide; DM 5 alveolar-capillary membrane-diffusing capacity; FEV1 5 forced expiratory volume in 1s; LVEF 5 left
ventricular ejection fraction; MR 5 mitral regurgitation; Na 5 sodium; rap 5 right atrial pressure; SBP 5 systolic blood pressure;
TLC 5 total lung capacity; Vc9 5 pulmonary capillary blood volume; VC 5 vital capacity; WPP 5 wedge pulmonary pressure.
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subjectively on a scale from 0 (none) to 5 (severe). Two-
dimensional echocardiography was the modality used to
measure LVEF (Simpson’s rule) at rest. Measurements of
HCT were corrected for trapped plasma volume and for
whole-body HCT. Aldosterone plasma concentration and
PRA were determined by radioimmunoassay. Norepineph-
rine was measured by high performance liquid chromatog-
raphy. Urine electrolytes were measured by ion-selective
electrodes.
Statistical analysis. Data are expressed as the mean
value 6 SD. Statistical analysis was performed by using
two-way repeated-measures analysis of variance, Newman-
Keuls multiple comparison procedures (post hoc analysis
was not performed unless analysis of variance reached
statistical significance) and linear regression. A p value
,0.05 was considered significant.
RESULTS
In groups 1 and 2, demographic data, blood pressure, renal
function, urinary water and sodium excretion and drug
treatments were comparable; right atrial and wedge pulmo-
nary pressures at rest were within normal limits; cardiac
index and LVEF were reduced; and forced expiratory
volume in 1 s, vital and total lung capacities and DCO were
lower than the predicted normal values (Table 1). In the two
groups in the control condition, baseline HCT, hemoglobin
and plasma protein concentrations were normal; baseline
plasma aldosterone and NE concentrations and PRA ex-
ceeded normal values (Table 2). There were no significant
differences in the pre-infusion data between sessions, both
in the control condition and during drug treatment. No
patient had symptoms or complaints during the studies.
In group 1, immediately after the 150-ml infusion, we
recorded a significant reduction in aldosterone, PRA and
DM/VA; a trend toward a slight decrease of HCT, hemo-
globin and plasma protein concentrations; and a significant
increase of NE (Table 2). We also recorded a decrease with
saline of DCO and DM and an increase in Vc9 (Fig. 2). These
responses were somewhat greater after the 750-ml solution
and were not associated with variations in the cardiac index,
LVEF (Table 2) or right atrial and pulmonary capillary
wedge pressures (Fig. 2). After giving patients enalapril for
two weeks, baseline aldosterone was lowered and PRA was
raised, as compared with baseline values in the control
condition. There was also some increase in the cardiac
index, as well as a decrease in the pulmonary wedge pressure
and arteriolar resistance; none of these variations, however,
was significant. The DM/VA, DCO and DM values at rest
were significantly augmented with enalapril, and the in-
crease in DM did not show a relation with the effects on
pulmonary arteriolar resistance. The percent decreases in
DM/VA, DCO and DM with saline were unchanged as
compared with those values before enalapril treatment (Fig.
3). Because of this, their absolute values reached after saline
Table 2. Mean Baseline Values of Cardiac, Pulmonary, Hematologic and Humoral Variables in the Control Condition, During
Enalapril and Losartan Treatment, and Their Average Percent Variations From Baseline Immediately After 150-ml and 750-ml
Saline Infusions in Group 1 Patients
150 ml Saline
Control Enalapril Losartan
Baseline D% Baseline D% Baseline D%
LVEF (%) 30 6 5.0 0.5 6 0.1 33 6 5.0 0.6 6 0.2 31 6 4.0 0.3 6 0.2
CI (ml/min per m2) 2,347 6 400 2 6 1.0 2,420 6 500 4 6 1.0 2,405 6 350 5 6 2.0
DM/VA (ml/min per mm Hg) 5.6 6 3.0 25.2 6 4.0* 6.1 6 3.0† 25.5 6 2.0* 5.5 6 2.5 25.4 6 3.0*
HCT (%) 41 6 4.0 20.9 6 0.2 39.1 6 3.0 20.2 6 0.1 39.9 6 4.0 20.3 6 0.2
Hb (g/dl) 13.7 6 2.0 20.9 6 0.3 13.2 6 1.5 20.3 6 0.2 13.5 6 1.7 20.5 6 0.1
PPC (g/dl) 6.7 6 3.0 0.2 6 0.5 6.7 6 2.0 1.5 6 0.8 6.6 6 2.5 0.7 6 0.3
Aldosterone (pg/ml) 260 6 50 210.3 6 7.0* 143 6 45† 27.7 6 7.0*† 152 6 39† 26.2 6 6.1*†
PRA (ng/ml per h) 5.0 6 2.0 214.5 6 8.0* 9.9 6 3.0† 222 6 9.0*† 10.2 6 4.0† 218.3 6 7.0*†
NE (pg/ml) 440 6 100 24 6 15§ 452 6 90 210 6 8.0*† 405 6 85 213 6 6.0*†
750 ml Saline
Baseline D% Baseline D% Baseline D%
LVEF (%) 32 6 6.0 1.0 6 0.3 35 6 5.0 0.8 6 0.2 33 6 4.0 1.1 6 0.8
CI (ml/min per m2) 2,310 6 380 3.0 6 1.5 2,390 6 350 5.0 6 2.0 2,415 6 270 4.0 6 2.6
DM/VA (ml/min per mm Hg) 5.6 6 2.0 26.1 6 4.0* 6.2 6 2.0† 26.3 6 2.0*† 5.3 6 2.1 26.7 6 3.0*
HCT (%) 40.4 6 4.0 25.5 6 2.0*‡ 39.6 6 5.0 27 6 3.0*‡ 41.1 6 3.0 28 6 2.0*‡
Hb (g/dl) 13.6 6 2.5 25.7 6 2.0*‡ 13.2 6 2.0 25.2 6 2.0*‡ 13.5 6 1.9 25.8 6 1.8*‡
PPC (g/dl) 6.6 6 3.0 25.7 6 2.0*‡ 6.6 6 3.0 26.0 6 2.7*‡ 6.6 6 2.0 25.9 6 2.0*‡
Aldosterone (pg/ml) 251 6 40 235 6 8*‡ 140 6 40† 235.7 6 9.0*‡ 158 6 32† 230.4 6 6.0*‡
PRA (ng/ml per h) 5.2 6 2.0 248 6 15*‡ 10.1 6 4.0† 228 6 10*† 11 6 3.1† 233 6 12*‡
NE (pg/ml) 450 6 90 40 6 15*‡ 449 6 85 29 6 4*† 397 6 78 215 6 5.0*†
*p , 0.01 versus baseline. †p , 0.01 versus control condition. ‡p , 0.01 versus 150 ml saline. Data are presented as mean value 6 SD.
Hb 5 hemoglobin; HCT 5 hematocrit; NE 5 norepinephrine; PPC 5 plasma protein concentration; PRA 5 plasma renin activity; VA 5 alveolar volume; other abbreviations
as in Table 1.
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turned out to be significantly greater after than those before
enalapril (Fig. 2). While the patients took enalapril, saline
caused a greater increase of Vc9 (Fig. 2) and reduced plasma
NE (Table 2). Right atrial and pulmonary capillary wedge
pressures did not vary with saline. The time course of the
pulmonary response was not affected by enalapril (Fig. 2).
After giving these same patients losartan for two weeks,
baseline aldosterone was reduced and PRA was increased as
compared with those values at baseline in the control
condition; DM/VA, DCO and DM at rest reverted to values
comparable to the control ones, and saline infusions brought
them down to levels similar to those attained before enala-
pril. AT1 receptor blockade was not effective on the time
course of the pulmonary response to saline; during losartan
treatment, right atrial and pulmonary wedge pressures did
not vary significantly with infusion of saline (Table 2 and
Fig. 4).
In group 2, the effects of the ACE inhibitor on the
Figure 2. Pulmonary diffusion capacity for carbon monoxide (DCO), alveolar-capillary membrane-diffusing capacity (DM), pulmonary capillary blood
volume (Vc9), mean wedge pulmonary pressure (wpp) and mean right atrial pressure (rap) in group 1 patients before and after 150-ml and 750-ml saline
infusions in the absence (open circles) and presence (solid circles) of enalapril in the therapeutic regimen. *p , 0.01 vs. baseline. Dp , 0.01 vs.
corresponding value before enalapril treatment.
Figure 3. Respiratory average percent variations in group 1 patients from
before to immediately after 150-ml and 750-ml saline infusions in the
control condition (open columns) and after enalapril treatment (solid
bars). *p , 0.01 vs. control condition. Abbreviations as in Figure 2.
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examined variables at rest, as well as the response to saline,
were comparable to those in group 1. With the combination
of enalapril with aspirin, as compared with enalapril alone,
there were no changes in the baseline cardiac index, LVEF,
circulating NE or aldosterone; DCO, DM, DM/VA and Vc9
at rest and their responses to saline reverted to levels similar
to the control ones (Fig. 5). The counteracting effect of
aspirin resulted in abolition of the benefits of enalapril on
the alveolar-capillary membrane gas transfer.
DISCUSSION
Angiotensin-converting enzyme inhibition was able to pre-
serve the pulmonary gas transfer in patients with CHF, both
at rest and when the alveolar-capillary membrane was
challenged with a salt-mediated increase in diffusion resis-
tance. Enalapril, in fact, augmented DCO, DM and DM/VA
at rest. The percent depression of these variables with
infusion of saline was similar in the presence and absence of
ACE inhibition. A similar percent reduction of an increased
value of DM suggests that the greater the improvement of
DM at rest, the lower the influence of saline on diffusion
resistance. According to this, absolute levels of DCO, DM
and DM/VA reached during saline infusion were signifi-
cantly higher than those before enalapril. AT1 receptor
blockade with losartan failed to provide the same results.
Effects of saline. We chose to infuse an amount of saline
(150 ml) similar to the accepted value for pulmonary
Figure 4. Pulmonary diffusion capacity for carbon monoxide (DCO), alveolar-capillary membrane-diffusing capacity (DM), pulmonary capillary blood
volume (Vc9), mean wedge pulmonary pressure (wpp) and mean right atrial pressure (rap) in group 1 patients before and after 150-ml and 750-ml saline
infusions in the absence (open circles) and presence (solid triangles) of losartan in the therapeutic regimen. *p , 0.01 vs. baseline.
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capillary blood volume in humans in a supine position (18),
as well as a fivefold greater amount. We reasoned that,
because ACE inhibition and AT1 receptor blockade inter-
fere with the same hormones (PRA, aldosterone and NE)
involved in the humoral reaction to saline, the use of
different amounts of solution with different humoral-
stimulating properties would bring greater understanding to
the mechanisms of drug action.
Conditions causing an expansion in circulating volume,
or movement of blood from the periphery to the thorax (19),
are associated with an acute increase in Vc9, DM and DCO.
In our patients, saline infusion produced an increase of the
capillary blood volume available for gas exchange (Vc9), as
well as a decrease in DCO, DM and DM/VA. An abrupt fall
in DM suggests the development of acute changes in the
membrane-diffusing properties. A number of factors make it
likely that, in CHF, saline causes subclinical interstitial
pulmonary edema, due to an upregulated sodium transport
across the microvascular endothelium barrier, which results
in DM being reduced: there were no changes in hydrostatic
forces; the decrease in conductance was prompt and disap-
peared within less than 1 h; impedance to gas transfer
presumably was greater than that gathered from the assess-
ment of DM, because it was such as to overcome the
opposing effects of increased Vc9; and the response to saline
varied in parallel with the amount of solution infused, even
though the relation was not linear. Possible reasons for this
might be a greater rise in interstitial fluid pressure with a
greater amount of saline, a dilution of interstitial proteins
and increased lymph flow (20,21). Development of intersti-
tial pulmonary edema would be expected to affect gas
exchange by augmenting the thickness of the alveolar-
capillary membrane, by reducing the compliance of alveoli
and by compressing small blood vessels, resulting in non-
uniform air flow and blood flow distribution.
Enalapril versus losartan. As to the process underlying the
benefits of enalapril on gas conductance and the failure of
losartan to provide the same results, the interpretations are
more complex. Changes in aldosterone and NE do not seem
to have a role because they were similar with the two drugs;
with enalapril, DM improved at rest when aldosterone was
reduced and NE was steady, and it worsened with saline
when NE was inhibited and aldosterone was further dimin-
ished. These humoral changes were greater with the 750-ml
Figure 5. Pulmonary diffusion capacity for carbon monoxide (DCO), alveolar-capillary membrane-diffusing capacity (DM) and pulmonary capillary blood
volume (Vc9) before and after 150-ml and 750-ml saline infusions in the control condition (open circles), with enalapril alone (solid circles) and after
combining aspirin with enalapril (solid squares). *p , 0.05 vs. baseline. Dp , 0.05 vs. corresponding control value. #p , 0.05 vs. corresponding enalapril
value.
404 Guazzi et al. JACC Vol. 37, No. 2, 2001
Pulmonary Gas Exchange in CHF February 2001:398–406
as compared with the 150-ml solution, but differences in the
DM response to the two saline amounts were much smaller.
A hypothetical participation of the enalapril-mediated ad-
renergic inhibition in the protection of gas diffusion (22) is
inconsistent with the DM improvement with enalapril at
rest, as it was not associated with changes in circulating NE.
Although a loss of the gas transfer protective action of
enalapril with aspirin in CHF has already been shown
(3,10), we considered it important to demonstrate in this
study that aspirin is adverse not only at rest but also under
sodium challenge. This demonstration in group 2 suggests
that vasodilating prostaglandins are a likely key mechanism
for the protection of the alveolar-capillary function that
enalapril exerts in either condition. Failure of the AT1
receptor blocker conforms to this interpretation, as this drug
category is devoid of significant prostanoid-stimulating
properties.
Mechanisms of action. The answer to the basic question
of whether the target of the prostaglandin action is the
transport of sodium across the microvascular barrier is not
an easy one. Considerations in favor of such a possibility
include a fundamental role of prostaglandins in the preser-
vation of endothelial integrity, capillary tone and permeabil-
ity (23) and in the maintenance of normal pulmonary fluid
conductance (24); and enhancement, instead of a reduction,
of the gas diffusion with ACE inhibition (the greater Vc9
increase with saline infusion during enalapril treatment, in
fact, may be expected to raise [25] the pulmonary micro-
vascular pressure and fluid filtration). In a recent report (5),
no measurable improvement of DCO and DM was seen in
the first 48 h after starting enalapril, whereas a significant
increase in these variables was apparent at studies repeated
after a week. This might suggest that preservation of
membrane gas transfer consists of a regression of the
structural abnormalities through an inhibition of the
angiotensin-mediated synthesis of collagen. Collagen has,
in fact, a pivotal role in the cardiogenic stress failure of the
alveolar-capillary barrier (1). This interpretation, however,
is contradicted by the inefficacy of losartan. The hypothesis
that collagen turnover is impeded through activation of the
prostaglandin synthesis (26) implies the unconvincing pos-
sibility that structural improvement of the membrane with
enalapril regresses within a week or less under the influence
of aspirin. We therefore suggest that the balance of evidence
argues in favor of a modulation, by enalapril, of an upregu-
lated sodium transport across the pulmonary endothelium in
patients with CHF. The increased hydrostatic load would
be the initiator of the alveolar-capillary membrane stress
failure (1), which, once developed, would persist (27), even
if the stimulus is abolished by drug treatment or heart
transplantation, and mediate a disordered salt and water
metabolism.
Conclusions. Enalapril exerts a prostaglandin-mediated
protective influence on alveolar-capillary membrane gas
diffusion in patients with CHF, probably through a modu-
lation of an upregulated sodium handling by the pulmonary
microvascular endothelial barrier. Losartan does not share
these properties. These notions are interesting in their own
right, and possibly have wider clinical and therapeutic
implications in this group of patients, in view of the peculiar
exposure to the risk of salt retention.
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